Chemed (CHE) Surpasses Q4 Earnings and Revenue Estimates

Core Viewpoint - Chemed reported quarterly earnings of $6.83 per share, exceeding the Zacks Consensus Estimate of $6.79 per share, and showing an increase from $6.60 per share a year ago [1][2] Financial Performance - The company achieved revenues of $639.99 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.78% and up from $585.91 million year-over-year [3] - Chemed has surpassed consensus revenue estimates two times over the last four quarters [3] Stock Performance - Chemed shares have increased approximately 3.9% since the beginning of the year, compared to a 1.3% gain in the S&P 500 [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $5.55 on revenues of $623.53 million, and for the current fiscal year, it is $25.10 on revenues of $2.57 billion [8] - The estimate revisions trend for Chemed is mixed, which may change following the recent earnings report [7] Industry Context - Chemed operates within the Medical - Outpatient and Home Healthcare industry, which is currently ranked in the top 24% of over 250 Zacks industries [9] - The industry has shown a strong correlation between near-term stock movements and trends in earnings estimate revisions [6]